Chemotherapy- and Irradiation-Induced Bone Loss in Adults with Solid Tumors
| Autor: | Michel D. Wissing |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2015 |
| Předmět: |
Oncology
Adult medicine.medical_specialty Drug-Related Side Effects and Adverse Reactions Endocrinology Diabetes and Metabolism medicine.medical_treatment Antineoplastic Agents Bone resorption Drug Therapy Internal medicine Neoplasms Solid tumors medicine Humans Bone Resorption Radionuclides Radioisotopes Chemotherapy Diphosphonates Radiotherapy business.industry Cancer Imatinib Antiresorptive agents medicine.disease Surgery Osteoporosis and Cancer (P Clezardin and G van der Pluijm Section Editors) Radiation therapy Imatinib mesylate Denosumab Methotrexate Imatinib Mesylate Chemotherapy-induced bone loss Taxoids Radiotherapy-induced bone loss business medicine.drug |
| Zdroj: | Current Osteoporosis Reports |
| ISSN: | 1544-2241 1544-1873 |
| Popis: | It is estimated that bone loss occurs in 70 % of all patients dying from cancer, causing a significant disease burden in cancer patients. Bone loss is caused by cancer itself and its metastases, but also by cancer therapies. Of the cancer therapy-induced bone loss, hormone therapies are best known for their bone damaging abilities. However, chemo- and radiotherapy may result in bone loss too. In this review, direct and indirect effects of various chemotherapies (such as methotrexate, imatinib, and taxanes) that cause bone loss are discussed. Furthermore, we discuss bone loss caused by radiotherapy and radionuclides, of which the latter may be reduced with the introduction of the alpha-emitter Radium-223. Finally, agents preventing chemotherapy- or radiotherapy-induced bone loss, in particular denosumab and bisphosphonates, are being reviewed for their efficacy in preventing chemotherapy- and irradiation-induced bone loss in cancer patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink